Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash from Investing Activities (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Cash from Investing Activities for 4 consecutive years, with -$123000.0 as the latest value for Q4 2024.

  • Quarterly Cash from Investing Activities rose 37.88% to -$123000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$123000.0 through Sep 2025, up 62.61% year-over-year, with the annual reading at -$254000.0 for FY2024, 66.97% up from the prior year.
  • Cash from Investing Activities for Q4 2024 was -$123000.0 at Werewolf Therapeutics, down from -$3000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was -$3000.0 in Q3 2024, with the low at -$2.0 million in Q3 2022.
  • Average Cash from Investing Activities over 4 years is -$320750.0, with a median of -$145500.0 recorded in 2023.
  • The sharpest move saw Cash from Investing Activities plummeted 1815.69% in 2022, then surged 98.64% in 2024.
  • Over 4 years, Cash from Investing Activities stood at -$272000.0 in 2021, then tumbled by 90.44% to -$518000.0 in 2022, then skyrocketed by 61.78% to -$198000.0 in 2023, then surged by 37.88% to -$123000.0 in 2024.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$123000.0, -$3000.0, and -$17000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.